# Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)

> **NCT00173888** · PHASE2 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 15 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Docetaxel, Cisplatin
- **DRUG:** Gemcitabine, Cisplatin

## Key facts

- **NCT ID:** NCT00173888
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2012-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00173888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00173888, "Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00173888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*